Pharmacotherapy of lgG4-related disease

Igg4-Related Disease

Volumn , Issue , 2014, Pages 45-50

  Kawano, Mitsuhiro ^a   Yamada, Kazunori ^a   Nishiyama, Susumu ^b   Kawa, Shigeyuki ^c  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^b University of Tokyo   (Japan)

^c SHINSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84922610066     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-4-431-54228-5_8     Document Type: Chapter

References (30)

1. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med. 2012;366(6):539-51.
2. Chari ST, Murray JA. Autoimmune pancreatitis, Part II: the relapse. Gastroenterology. 2008;134(2):625-8.
3. Nakano S, Takeda I, Kitamura K, et al. Vanishing tumor of the abdomen in patient with Sjogren's syndrome. Dig Dis. 1978;23:75-9.
4. Ito T, Nishimori I, Inoue N, et al. Treatment for autoimmune pancreatitis: consensus on the treatment for patients with autoimmune pancreatitis in Japan. J Gastroenterol. 2007;42 Suppl 18:50-8.
5. Kamisawa T, Okazaki K, Kawa S, et al. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol. 2010;45(5):471-7.
6. Kubota K, Watanabe S, Uchiyama T, et al. Factors predictive of relapse and spontaneous remission of autoimmune pancreatitis patients treated/not treated with corticosteroids. J Gastroenterol. 2011;46(6):834-42.
7. Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard glucocorticoid treatment for autoimmune pancreatitis. Gut. 2009;58(11): 1504-7.
8. Kamisawa T, Yoshiike M, Egawa N, et al. Treating patients with autoimmune pancreatitis: results from a long-term follow-up study. Pancreatology. 2005;5(2 3):234-8. discussion 8–40.
9. Kamisawa T, Okamoto A, Wakabayashi T, et al. Appropriate gluco-corticoid therapy for autoimmune pancreatitis based on long-term outcome. Scand J Gastroenterol. 2008;43(5):609-13.
10. Nishino T, Toki F, Oyama H, et al. Long-term outcome of autoimmune pancreatitis after oral prednisolone therapy. Intern Med.2006;45(8):497-501.
11. Nishimori I, Tamakoshi A, Kawa S, et al. Influence of glucocorticoid therapy on the course of diabetes mellitus in patients with autoimmune pancreatitis: findings from a nationwide survey in Japan. Pancreas. 2006;32(3):244-8.
12. Kawa S, Hamano H, Ozaki Y, et al. Long-term follow-up of autoimmune pancreatitis: characteristics of chronic disease and recurrence. Clin Gastroenterol Hepatol. 2009;7(11 Suppl):S18-22.
13. Takayama M, Hamano H, Ochi Y, et al. Recurrent attacks of autoimmune pancreatitis result in pancreatic stone formation. Am J Gastroenterol. 2004;99(5):932-7.
14. Maruyama M, Arakura N, Ozaki Y, et al. Risk factors for pancreatic stone formation in autoimmune pancreatitis over a long-term course. J Gastroenterol. 2011;47(5):553-60.
15. Kawa S, Hamano H. Clinical features of autoimmune pancreatitis. J Gastroenterol. 2007;18(42 Suppl):9-14.
16. Muraki T, Hamano H, Ochi Y, et al. Autoimmune pancreatitis and complement activation system. Pancreas. 2006;32(1):16-21.
17. Matsushita M, Yamashina M, Ikeura T, et al. Effective glucocorti-coid pulse therapy for the biliary stenosis caused by autoimmune pancreatitis. Am J Gastroenterol. 2007;102(1):220-1.
18. Church NI, Pereira SP, Deheragoda MG, et al. Autoimmune pancreatitis: clinical and radiological features and objective response to glucocorticoid therapy in a UK series. Am J Gastroenterol. 2007; 102(11):2417-25.
19. Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134(3):706-15.
20. Topazian M, Witzig TE, Smyrk TC, et al. Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated chol angitis. Clin Gastroenterol Hepatol. 2008;6(3):364-6.
21. Sandanayake NS, Church NI, Chapman MH, et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2009;7(10):1089-96.
22. Raina A, Yadav D, Krasinskas AM, et al. Evaluation and management of autoimmune pancreatitis: experience at a large US center. Am J Gastroenterol. 2009;104(9):2295-306.
23. Ghazale A, Chari ST. Optimising corticoglucocorticoid treatment for autoimmune pancreatitis. Gut. 2007;56(12):1650-2.
24. Masaki Y, Dong L, Kurose N, et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis. 2009;68(8):1310-5.
25. Yamamoto M, Harada S, Ohara M, et al. Beneficial effects of glucocorticoid therapy for Mikulicz's disease. Rheumatology (Oxford). 2005;44(10):1322-3.
26. Kawano M, Yamada K. Treatment of IgG4-related disease. Curr Immunol Rev. 2011;7:246-51.
27. Saeki T, Nishi S, Imai N, et al. Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis. Kidney Int. 2010;78(10):1016-23.
28. Raissian Y, Nasr SH, Larsen CP, et al. Diagnosis of IgG4-related tubulointerstitial nephritis. J Am Soc Nephrol. 2011;22(7): 1343-52.
29. Mizushima I, Yamada K, Fujii H, et al. Clinical and histological changes associated with corticoglucocorticoid therapy in IgG4-related tubulointerstitial nephritis. Mod Rheumatol. 2012;22(6):859-70.
30. Ebbo M, Daniel L, Pavic M, et al. IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. Medicine (Baltimore). 2012;91(1):49-56.